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Background: Somatostatin has been found to be effective in the prevention of postoperative 
complications in pancreatic surgery. It can inhibit the pancreatic secretions that, quite often, 
are responsible for complications during the postoperative period.
Methods: We randomized 67 patients in 2 groups. In the study group (n = 35), somatostatin 
was administered 30 minutes prior to surgery as well as intraoperatively and postoperatively. 
No medication was given to the control group (n = 32). Biopsies were taken and processed for 
electron microscopy and ultrastructural morphometric analysis.
Results: Administration of somatostatin reduced the exocrine granule number, and the patients 
suffered from fewer postoperative complications.
Conclusions: Somatostatin reduces granule number and size of pancreatic cells, which can 
partially explain the prophylactic effect of the drug on early complications of pancreatic surgery, 
and which is confirmed by the clinical findings.
Keywords: electron microscopy, pancreatic resection, somatostatin, complication, histological 
findings
Introduction
Release and activation of pancreatic enzymes during an operation and the postopera-
tive period are responsible for complicating pancreatic surgery.1,2 Somatostatin can 
inhibit pancreatic exocrine secretion.3–8
Somatostatin involves a broad range of biological actions, which include the inhibition 
of pancreatic exocrine secretion. The actions of somatostatin are mediated by a family of 
7 transmembrane-based G-protein-coupled receptors that comprise 5 distinct subtypes 
(SSTR1-5). The receptors have common signaling pathways such as inhibition of adenyl 
cyclase, activation of phosphotyrosine phosphatase, and modulation of mitogen-activated 
protein kinase. The mechanisms whereby somatostatin receptors transduce messages into 
intracellular responses under different conditions and in different cells are complex.
Inhibition of pancreatic exocrine secretion should improve the postoperative course 
and consequently reduce complications after pancreatic resection.9
The aim of this study was to assess the effect of somatostatin administration on 
the ultra-structure of exocrine pancreatic cells by comparing electron microscopy 
with clinical results.
Methods
Patients
Consecutive patients suffering mainly from pancreatic tumor (n = 60/67) and chronic 
pancreatitis (n = 9/67) that were suitable for pancreatic resection were enrolled in Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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the study (Table 1). The patients who met the preliminary 
criteria were randomly assigned to receive a continuous 
intravenous infusion of somatostatin-14 (Somastin Sb, 
Faran, Athens, Greece). The dose was 3000 mg within 
12 hours at an infusion rate of 3.5 mg/kg/h, perioperatively 
(30 minutes before surgery, intraoperatively, and 7 days after 
surgery). The study group consisted of 35 patients and the 
control group 32. Patients were maintained on their usual 
diet and fasted for 12 hours before surgery. No patient was 
on total parenteral nutrition. Each patient received intrave-
nous antibiotic prophylaxis 30 minutes preoperatively and 
a second dose 3 hours after the start of the operation. All 
patients were treated in the intensive care unit for the first 
24 hours. Intravenous crystalloid solutions were adminis-
trated (2.5–3.0 L/d) according to clinical requirements and 
these were supplemented by plasma or blood components 
in order to maintain a positive central venous pressure and 
a blood hemoglobin $8–9 g/dL. The patients were given 
nothing orally during the first 3 postoperative days. Each 
patient was traced up to the 90th postoperative day. The 
patients were treated according to the ethical guidelines of 
the World Medical Association Declaration of Helsinki – 
Ethical Principles for Medical Research Involving Human 
Subjects adopted by the 18th WMA General Assembly, 
Helsinki, Finland, June 1964, as revised in Tokyo 2004. 
All participants gave informed consent to participation 
before enrolment.
study design
The study was an open-label, parallel-group, simple random-
ized clinical trial and the patients were selected according 
to the CONSORT (Consolidated Standards of Reporting 
Trials) criteria.
The operations were performed and all data were col-
lected at the hospital-based surgical department at the General 
Hospital “Agios Dimitrios”, Thessaloniki, Greece.
The statistical analysis was performed using SPSS soft-
ware (v. 15.0.1.1; SPSS Inc., Chicago, IL, USA).
The histopathological assessment and the morphometric 
analysis were performed at the department of Histology and 
Embryology, School of Medicine, Aristotelian University of 
Thessaloniki. The review was standardized. It was performed 
by the same pathologist, who was blinded to the study group 
of the patients.
Operative procedures
After induction of general anesthesia, 13 patients underwent 
Kausch–Whipple operation, 46 Traverso–Longmire, 
5 patients distal pancreatectomy and spleenectomy, and 1 dis-
tal pancreatectomy with preservation of the spleen (Table 2). 
All patients were operated on by the same surgical team using 
the same technique and type of materials. A 2-layer technique 
of end-to-side pancreatojejunal anastomosis was performed 
with 5/0 Monosyn® (B. Brawn Aesculap Melsungen AG) 
and 4/0 PDSII® (Ethicon), an end-to-side 1-layer choledo-
chojejunal anastomosis was performed with 4/0 PDSII, and 
a 1-layer gastrojejunal anastomosis was performed with 4/0 
Monosyn. The total operative time was an average of 6 hours 
for the Kausch–Whipple or Traverso–Longmire operation 
and 4 hours for the distal pancreatectomy. All patients, with 
the exception of those who underwent distal pancreatectomy, 
were transferred to the intensive care unit.
histopathology
After the division of the pancreas, a small piece from 
the healthy tissue (pancreatic remnant) was taken for 
electron microscope histopathological assessment. The 
mean time between injection of somatostatin, tissue resec-
tion, and fixation was 3 hours. The samples were cut into 
smaller pieces (1 mm3) and fixed in 3% glutaraldehyde 
in phosphate buffer pH 7.4 for 2 hours and postfixed in 
2% osmium tetroxide for 1 hour. After staining with 1% 
aqueous solution of uranyl acetate for 14 hours, the tissue 
pieces were dehydrated in an increasing series of alcohol 
solutions and then embedded in EPON 812. After the 
observation of the morphology on the semi-thin sections 
stained with toluidine blue, thin sections were stained with 
lead citrate and then observed in a Jeol TEM 2000FXII 
at 80 kV (Table 3).
Table 1 Demographic findings
Total 
n = 67
With 
treatment 
n = 35
Without 
treatment 
n = 32
Age 61.1 (37–84) 62.7 (37–84) 61.3 (41–83)
sex (M/F) 39/28 22/13 17/15
Table 2 surgical data
Total 
n = 67
With 
treatment 
n = 35
Without 
treatment 
n = 32
P value
Longmire–Traverso 46 23 23 0.585
Kausch–Whipple 13 8 5 0.45
Distal pancreatectomy + 
spleenectomy
7 4 3 0.783
Distal pancreatectomy 1 0 1 0.31Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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Results
Clinical findings
Within 90 days of surgery, surgical mortality was 4.4% and 
morbidity was 35.8% (24/67 patients, 6 of whom were from 
the somatostatin group and 18 from the control group). The 
most frequent complication (Table 4) was fistula (25%) 
followed by abscess (20.8%), delayed gastric emptying, 
upper respiratory infection, urinary tract infection, fever, 
and multi-organ failure. The frequency of postoperative 
complications was lower in the somatostatin group than 
in the control group (Table 5). The levels of bilirubin and 
amylase were calculated both in serum and surgical drainage 
during the first, third, and fifth postoperative day in order 
to establish the presence of fistula or anastomosis leakage. 
Initially, hypoglycemia followed by hyperglycemia due 
to inhibition of insulin secretion, nausea, vomiting, and 
a burning sensation were the most common side effects 
of somatostatin. Mild side effects that did not rule out the 
interruption of the drug were observed in 3 patients who 
received somatostatin. Skin rash developed in 2 patients, 
and nausea with vomiting in one of these.
Histological findings
In control patients the acini were normal with many mem-
brane-bound granules of variable size, dilated rough endo-
plasmic reticulum, and many Golgi complexes (Figures 1 
and 2).
Also, we observed dense connective tissue between the 
acini, some destroyed cells, and some cells with pycnotic 
nucleus.
The fine structure of the acinar cells after the administra-
tion of somatostatin was different. Many of the acinar cells 
had few granules or none at all. The electron density of 
membrane-bound granules varied. The cell organelles (rough 
endoplasmic reticulum, c. Golgi) were few (Figures 3 and 4). 
There were also acinar cells with a physiological appear-
ance and many granules, as in the case of the control group. 
A reduction in size was observed in almost all acinar cells 
in more than 80% of cases.
Table 3 histopathological diagnosis
Total 
n = 67
With 
treatment 
n = 35
Without 
treatment 
n = 32
Pancreatic 
adenocarcinoma
53 29 24
Pancreatitis 9 5 4
neuroendocrine 
tumor
1 0 1
Metastatic 
adenocarcinoma
1 0 1
Lymphoma 1 0 1
Acinar cell 1 1 0
Cystadenoma 1 0 1
Figure  1  Control  patient.  Acinar  cells  with  very  dilated  rough  endoplasmic   
reticulum (rer).
Abbreviation: n, nucleus × 8000.
Table 4 Definition of complications
Pancreatic fistula Peritoneal amylase levels (drain) . 3× plasma 
amylase from day 3 onwards (international study 
Group on Pancreatic Fistula Definition)
intra-abdominal 
collection
sterile liquid collection of at least 5 × 5 cm 
diagnosed on abdominal CT or ultrasonography
intra-abdominal Infected liquid collection confirmed by positive culture
abscess and diagnosed on abdominal CT or ultrasonography
sepsis 4 of the 5 following criteria: i. positive hemoculture; 
ii. fever .38°C; iii. WBC . 12,000/mm3  
or ,3000 mm3; iv. thrombocytopenia; 
v. metabolic acidosis
shock systolic pressure ,90 mmhg or a 30 mmhg drop in 
systolic pressure, altered organ perfusion
Abbreviation: CT, computed tomography; WBC, white blood cell count.
Table 5 Postoperative complications
Total With  
somatostatin
Without  
somatostatin
General
Pulmonary 1 (1.5%) 0 
Urinary tract infection 1 (1.5%) 0 
sepsis 0  3 (4.5%)
shock 1 (1.5%) 0
Multi-organ failure 1 (1.5%) 2 (3%)
Local
Fistula 1 (1.5%) 5 (7.5%)
intra-abdominal abscess 1 (1.5%) 3 (4.5%)
Intra-abdominal fluid 0 1 (1.5%)
Delayed gastric emptying 1 (1.5%) 2 (3%)
Wound dehiscence 0 2 (3%)
Wound infection 0 1 (1.5%)Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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Figure  2  Control  patient.  Acinar  cells  have  very  dilated  rough  endoplasmic 
reticulum (rer) and granules (gr).
Figure 3 Exocrine acini of pancreas, with administration of somatostatin.
Abbreviations: n, nucleus; m, mitochondria; rer, rough endoplasmic reticulum; 
gr, granules × 10,000.
Figure 4 Exocrine acini of pancreas, with administration of somatostatin. 
Abbreviation: n, nucleus × 5000.
Table 6 Morphometric results
Group Mean number 
of granules
Total granular 
area, μm2
Control  140 ± 7.16  70 ± 6.2 
somatostatin  101 ± 11.3  61 ± 5.7 
Note: Data expressed as mean values.
Selected tissue areas from the above specimens were 
randomized for morphometric analysis. Data were acquired 
by the same operator using dedicated software. In each area 
the number of granules and the total granular area were 
obtained (Table 6).
statistical analysis
Using several statistical methods we came to the following 
conclusions.
Initially, 6 of 35 (17%) in the treated group who received 
somatostatin developed complications, whereas 18 of 32 
(56%) in the control group developed complications. Then 
we hypothesized whether these two percentages were equal 
by using the simple test of equality, but this should be rejected 
because P = 0.000.
In order to be more accurate we used Fisher’s exact test, and 
came to the same conclusion (P = 0.001), ie, the percentages of 
the treated group and the control group are not equal.
Finally, with the help of logistic regression we concluded 
that the patients who did not receive somatostatin (control 
group) had a 6.2 times higher probability of developing 
complications than the treatment group.
Discussion
Many clinical studies have been performed since the first 
observation that somatostatin, and especially its synthetic 
analog octreotide, can modify pancreatic exocrine secretion. 
Most double-blind, placebo-controlled, randomized stud-
ies have shown that administration of somatostatin in the 
perioperative and preoperative period reduces postoperative 
complications of pancreatic resection, which are currently 
ascribed to excess release of pancreatic enzymes.10 However, 
a meta-analysis of randomized controlled trials has failed to 
show any benefit from the administration of somatostatin, 
especially if the administration was done only after surgery.11 
Finally, a systemic review of the Cochrane database has 
revealed that somatostatin can reduce the complications 
associated with pancreatic surgery.12
The mechanism by which somatostatin and its analog oct-
reotide affect the exocrine secretion of the pancreas has not been 
adequately investigated. The administration of somatostatin 
reduces pancreatic enzyme secretion in response to exogenous 
cholecystokinin and secretin. Gullo and other researchers have 
shown that somatostatin can reduce amino acid uptake by the 
pancreas with a consequent reduction of enzymic synthesis Clinical and Experimental Gastroenterology
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and release, while others have demonstrated that somatostatin 
acts indirectly on acinar cells and inhibits secretin potentiation 
of secretory response by inhibiting secretin-induced c-AMP 
production as well as the calcium sensitivity of exocytosis.13–15 
Moreover, somatostatin inhibits amylase secretion from isolated 
rat pancreatic acini. Other studies have suggested that soma-
tostatin inhibits pancreatic secretion when it is injected into a 
central vagal site via cholecystokinin octapeptide or 2-deoxy-
D-glucose-stimulated pancreatic protein secretion in a dose-
dependent manner, and that this inhibition is via somatostatin 
receptor-2.16,17 Somatostatin acts on the neurons in the central 
vagal site, resulting in modulation of the vagal tone, thereby 
inhibiting pancreatic enzyme secretion. The parasympathetic 
innervation of the pancreas plays a major role in the control of 
pancreatic exocrine secretion.
In our study, the number of patients who received 
somatostatin (treated group) was relatively small (n = 35). 
However, ultrastructurally we observed a reduction in the 
synthesis of pancreatic enzymes after the administration of 
somatostatin. The images revealed a smaller number of gran-
ules and changes in the synthetic machinery, as confirmed by 
morphometric analysis as well as by statistical analysis of the 
clinical results.
In conclusion, the perioperative administration of soma-
tostatin may provide some benefit in preventing pancreatic-
related complications by diminishing the synthesis of 
pancreatic enzymes, and is probably associated with the 
inhibition of exocrine secretion by the gland.
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